Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2010-05-18

AUTHORS

J Martinez-Trufero, D Isla, J C Adansa, A Irigoyen, R Hitt, I Gil-Arnaiz, J Lambea, M J Lecumberri, J J Cruz

ABSTRACT

BACKGROUND: Platinum-based therapy (PBT) is the standard therapy for recurrent and/or metastatic head and neck cancer (HNC), but the incidence of recurrence remains high. This study evaluates the efficacy and tolerability of capecitabine as palliative monotherapy for recurrent HNC previously treated with PBT. METHODS: Patients aged 18-75 years, with Eastern Cooperative Oncology Group performance status 0-2, squamous HNC with locoregional and/or metastatic recurrence previously treated with PBT and adequate organ functions, were included. Capecitabine (1.250 mg m(-2) BID) was administered on days 1-14 every 21 days for at least two cycles. RESULTS: A total of 40 male patients with a median age of 58 years were analysed. All patients received a median number of four cycles of capecitabine (range: 1-9) and the median relative dose intensity was 91%. Seven patients were not evaluable for response. Overall response rate was 24.2%. Median time to progression and overall survival were 4.8 and 7.3 months, respectively. Haematological adverse events (AEs) grade 3/4 were reported in six patients. Most common grade 3/4 non-haematological AEs were asthenia (12.5%), palmar-plantar eritrodisestesia (10%), mucositis (10%), dysphagia (10%) and diarrhoea (7.5%). CONCLUSIONS: Capecitabine seems to be an active, feasible and well-tolerated mode of palliative treatment for advanced HNC patients who have previously received PBT schedules. More... »

PAGES

1687-1691

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bjc.6605697

DOI

http://dx.doi.org/10.1038/sj.bjc.6605697

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1007753819

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20485287


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Capecitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Squamous Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Head and Neck Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Palliative Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Platinum Compounds", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department of University Hospital Miguel Servet Hospital, Paseo de Isabel La Cat\u00f3lica 1-3, 50009 Zaragoza, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411106.3", 
          "name": [
            "Medical Oncology Department of University Hospital Miguel Servet Hospital, Paseo de Isabel La Cat\u00f3lica 1-3, 50009 Zaragoza, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Martinez-Trufero", 
        "givenName": "J", 
        "id": "sg:person.01156301535.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156301535.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department of University Hospital Lozano Blesa Hospital, Avda. San Juan Bosco, 15, 50009 Zaragoza, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411050.1", 
          "name": [
            "Medical Oncology Department of University Hospital Lozano Blesa Hospital, Avda. San Juan Bosco, 15, 50009 Zaragoza, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Isla", 
        "givenName": "D", 
        "id": "sg:person.01103254434.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103254434.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department of University Hospital Cl\u00ednico de Salamanca Hospital, Paseo de San Vicente 58-182, 37007 Salamanca, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411258.b", 
          "name": [
            "Medical Oncology Department of University Hospital Cl\u00ednico de Salamanca Hospital, Paseo de San Vicente 58-182, 37007 Salamanca, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Adansa", 
        "givenName": "J C", 
        "id": "sg:person.01322547713.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322547713.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department of University Hospital Virgen de las Nieves Hospital, Avda de las Fuerzas Armadas, 18014 Granada, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411380.f", 
          "name": [
            "Medical Oncology Department of University Hospital Virgen de las Nieves Hospital, Avda de las Fuerzas Armadas, 18014 Granada, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Irigoyen", 
        "givenName": "A", 
        "id": "sg:person.01360660140.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01360660140.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department of University Hospital 12 de Octubre Hospital, Avda. de C\u00f3rdoba s/n, 28041 Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.144756.5", 
          "name": [
            "Medical Oncology Department of University Hospital 12 de Octubre Hospital, Avda. de C\u00f3rdoba s/n, 28041 Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hitt", 
        "givenName": "R", 
        "id": "sg:person.01132423736.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132423736.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department of University Hospital Miguel Servet Hospital, Paseo de Isabel La Cat\u00f3lica 1-3, 50009 Zaragoza, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411106.3", 
          "name": [
            "Medical Oncology Department of University Hospital Miguel Servet Hospital, Paseo de Isabel La Cat\u00f3lica 1-3, 50009 Zaragoza, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gil-Arnaiz", 
        "givenName": "I", 
        "id": "sg:person.01101151164.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101151164.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department of University Hospital Lozano Blesa Hospital, Avda. San Juan Bosco, 15, 50009 Zaragoza, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411050.1", 
          "name": [
            "Medical Oncology Department of University Hospital Lozano Blesa Hospital, Avda. San Juan Bosco, 15, 50009 Zaragoza, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lambea", 
        "givenName": "J", 
        "id": "sg:person.01320645107.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320645107.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department of University Hospital Miguel Servet Hospital, Paseo de Isabel La Cat\u00f3lica 1-3, 50009 Zaragoza, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411106.3", 
          "name": [
            "Medical Oncology Department of University Hospital Miguel Servet Hospital, Paseo de Isabel La Cat\u00f3lica 1-3, 50009 Zaragoza, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lecumberri", 
        "givenName": "M J", 
        "id": "sg:person.01331626164.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331626164.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department of University Hospital Cl\u00ednico de Salamanca Hospital, Paseo de San Vicente 58-182, 37007 Salamanca, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411258.b", 
          "name": [
            "Medical Oncology Department of University Hospital Cl\u00ednico de Salamanca Hospital, Paseo de San Vicente 58-182, 37007 Salamanca, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cruz", 
        "givenName": "J J", 
        "id": "sg:person.010151201132.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010151201132.46"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6602275", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033665397", 
          "https://doi.org/10.1038/sj.bjc.6602275"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6602849", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029288237", 
          "https://doi.org/10.1038/sj.bjc.6602849"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-05-18", 
    "datePublishedReg": "2010-05-18", 
    "description": "BACKGROUND: Platinum-based therapy (PBT) is the standard therapy for recurrent and/or metastatic head and neck cancer (HNC), but the incidence of recurrence remains high. This study evaluates the efficacy and tolerability of capecitabine as palliative monotherapy for recurrent HNC previously treated with PBT.\nMETHODS: Patients aged 18-75 years, with Eastern Cooperative Oncology Group performance status 0-2, squamous HNC with locoregional and/or metastatic recurrence previously treated with PBT and adequate organ functions, were included. Capecitabine (1.250 mg m(-2) BID) was administered on days 1-14 every 21 days for at least two cycles.\nRESULTS: A total of 40 male patients with a median age of 58 years were analysed. All patients received a median number of four cycles of capecitabine (range: 1-9) and the median relative dose intensity was 91%. Seven patients were not evaluable for response. Overall response rate was 24.2%. Median time to progression and overall survival were 4.8 and 7.3 months, respectively. Haematological adverse events (AEs) grade 3/4 were reported in six patients. Most common grade 3/4 non-haematological AEs were asthenia (12.5%), palmar-plantar eritrodisestesia (10%), mucositis (10%), dysphagia (10%) and diarrhoea (7.5%).\nCONCLUSIONS: Capecitabine seems to be an active, feasible and well-tolerated mode of palliative treatment for advanced HNC patients who have previously received PBT schedules.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bjc.6605697", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "12", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "102"
      }
    ], 
    "keywords": [
      "platinum-based therapy", 
      "palliative treatment", 
      "neck cancer", 
      "Eastern Cooperative Oncology Group performance status 0", 
      "median relative dose intensity", 
      "tolerability of capecitabine", 
      "performance status 0", 
      "adequate organ function", 
      "cycles of capecitabine", 
      "advanced HNC patients", 
      "relative dose intensity", 
      "phase II study", 
      "incidence of recurrence", 
      "overall response rate", 
      "platinum-based treatment", 
      "recurrent HNC", 
      "metastatic head", 
      "status 0", 
      "grade 3/4", 
      "dose intensity", 
      "II study", 
      "standard therapy", 
      "median age", 
      "overall survival", 
      "male patients", 
      "median time", 
      "metastatic recurrence", 
      "HNC patients", 
      "median number", 
      "squamous head", 
      "capecitabine", 
      "patients", 
      "day 1", 
      "organ function", 
      "response rate", 
      "recurrence", 
      "therapy", 
      "cancer", 
      "treatment", 
      "HNC", 
      "monotherapy", 
      "mucositis", 
      "tolerability", 
      "dysphagia", 
      "asthenia", 
      "diarrhea", 
      "years", 
      "head", 
      "incidence", 
      "recurrent", 
      "progression", 
      "months", 
      "efficacy", 
      "survival", 
      "age", 
      "total", 
      "study", 
      "days", 
      "response", 
      "schedule", 
      "rate", 
      "cycle", 
      "function", 
      "number", 
      "time", 
      "intensity", 
      "AES", 
      "mode", 
      "palliative monotherapy", 
      "Cooperative Oncology Group performance status 0", 
      "Oncology Group performance status 0", 
      "Group performance status 0", 
      "squamous HNC", 
      "Haematological adverse events (AEs) grade 3/4", 
      "adverse events (AEs) grade 3/4", 
      "events (AEs) grade 3/4", 
      "Most common grade 3/4 non-haematological AEs", 
      "common grade 3/4 non-haematological AEs", 
      "grade 3/4 non-haematological AEs", 
      "non-haematological AEs", 
      "palmar-plantar eritrodisestesia", 
      "eritrodisestesia", 
      "PBT schedules", 
      "metastatic squamous head", 
      "previous platinum-based treatment"
    ], 
    "name": "Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment", 
    "pagination": "1687-1691", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1007753819"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bjc.6605697"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20485287"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bjc.6605697", 
      "https://app.dimensions.ai/details/publication/pub.1007753819"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_522.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bjc.6605697"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605697'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605697'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605697'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605697'


 

This table displays all metadata directly associated to this object as RDF triples.

283 TRIPLES      22 PREDICATES      128 URIs      118 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bjc.6605697 schema:about N0191ab51a6e64c52b9a5bd4fb3f7bb9f
2 N1bc39d8de0d2499b8936f92d9448dd19
3 N3dd981293645441fa56af3f491236de6
4 N4aed640623744b7ea46c981faf91beae
5 N8b20078b14634b678b530736138ef6ae
6 N9ea93177178f4046baea281105ae7703
7 Nac4d76acc4dc409aaea8c41136c96207
8 Naec9de5c26284c7ca3e189d8025d8095
9 Nafb51ba3d3d1492680d17dd9b2d3750c
10 Nb392a6e194744b219cb8ea8e0505c939
11 Nb467d9069f674113b0bb513855b4d920
12 Nc53ab1faf5eb4db291c6ec0ff85db36e
13 Nce0c24b26aed4d03b96f2f10c7d17cca
14 Nddd0d97124554163b5929b01b9cbbda3
15 Nfaf5750f52f04dfa8920052ea2dfc8dc
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author Nfa7d12271bed4e228515ee87fc87571e
19 schema:citation sg:pub.10.1038/sj.bjc.6602275
20 sg:pub.10.1038/sj.bjc.6602849
21 schema:datePublished 2010-05-18
22 schema:datePublishedReg 2010-05-18
23 schema:description BACKGROUND: Platinum-based therapy (PBT) is the standard therapy for recurrent and/or metastatic head and neck cancer (HNC), but the incidence of recurrence remains high. This study evaluates the efficacy and tolerability of capecitabine as palliative monotherapy for recurrent HNC previously treated with PBT. METHODS: Patients aged 18-75 years, with Eastern Cooperative Oncology Group performance status 0-2, squamous HNC with locoregional and/or metastatic recurrence previously treated with PBT and adequate organ functions, were included. Capecitabine (1.250 mg m(-2) BID) was administered on days 1-14 every 21 days for at least two cycles. RESULTS: A total of 40 male patients with a median age of 58 years were analysed. All patients received a median number of four cycles of capecitabine (range: 1-9) and the median relative dose intensity was 91%. Seven patients were not evaluable for response. Overall response rate was 24.2%. Median time to progression and overall survival were 4.8 and 7.3 months, respectively. Haematological adverse events (AEs) grade 3/4 were reported in six patients. Most common grade 3/4 non-haematological AEs were asthenia (12.5%), palmar-plantar eritrodisestesia (10%), mucositis (10%), dysphagia (10%) and diarrhoea (7.5%). CONCLUSIONS: Capecitabine seems to be an active, feasible and well-tolerated mode of palliative treatment for advanced HNC patients who have previously received PBT schedules.
24 schema:genre article
25 schema:inLanguage en
26 schema:isAccessibleForFree true
27 schema:isPartOf N76901dcd8f084dbb873108c5182dac5d
28 N7e0a0537b0f04cee90c1e81922637ec3
29 sg:journal.1017082
30 schema:keywords AES
31 Cooperative Oncology Group performance status 0
32 Eastern Cooperative Oncology Group performance status 0
33 Group performance status 0
34 HNC
35 HNC patients
36 Haematological adverse events (AEs) grade 3/4
37 II study
38 Most common grade 3/4 non-haematological AEs
39 Oncology Group performance status 0
40 PBT schedules
41 adequate organ function
42 advanced HNC patients
43 adverse events (AEs) grade 3/4
44 age
45 asthenia
46 cancer
47 capecitabine
48 common grade 3/4 non-haematological AEs
49 cycle
50 cycles of capecitabine
51 day 1
52 days
53 diarrhea
54 dose intensity
55 dysphagia
56 efficacy
57 eritrodisestesia
58 events (AEs) grade 3/4
59 function
60 grade 3/4
61 grade 3/4 non-haematological AEs
62 head
63 incidence
64 incidence of recurrence
65 intensity
66 male patients
67 median age
68 median number
69 median relative dose intensity
70 median time
71 metastatic head
72 metastatic recurrence
73 metastatic squamous head
74 mode
75 monotherapy
76 months
77 mucositis
78 neck cancer
79 non-haematological AEs
80 number
81 organ function
82 overall response rate
83 overall survival
84 palliative monotherapy
85 palliative treatment
86 palmar-plantar eritrodisestesia
87 patients
88 performance status 0
89 phase II study
90 platinum-based therapy
91 platinum-based treatment
92 previous platinum-based treatment
93 progression
94 rate
95 recurrence
96 recurrent
97 recurrent HNC
98 relative dose intensity
99 response
100 response rate
101 schedule
102 squamous HNC
103 squamous head
104 standard therapy
105 status 0
106 study
107 survival
108 therapy
109 time
110 tolerability
111 tolerability of capecitabine
112 total
113 treatment
114 years
115 schema:name Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment
116 schema:pagination 1687-1691
117 schema:productId N00a5583abcd74fd3acfc87f4248994fd
118 N6ddbe258ac584c75b8e36db1445ad45b
119 N85e2295e725e44cb955c7951536f2d6d
120 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007753819
121 https://doi.org/10.1038/sj.bjc.6605697
122 schema:sdDatePublished 2021-12-01T19:24
123 schema:sdLicense https://scigraph.springernature.com/explorer/license/
124 schema:sdPublisher Nfe2a8b89cd16411b962b6abd7258acfe
125 schema:url https://doi.org/10.1038/sj.bjc.6605697
126 sgo:license sg:explorer/license/
127 sgo:sdDataset articles
128 rdf:type schema:ScholarlyArticle
129 N00a5583abcd74fd3acfc87f4248994fd schema:name dimensions_id
130 schema:value pub.1007753819
131 rdf:type schema:PropertyValue
132 N0191ab51a6e64c52b9a5bd4fb3f7bb9f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Adult
134 rdf:type schema:DefinedTerm
135 N0b39b6bda4724bba9e386a1857da9bb7 rdf:first sg:person.01132423736.65
136 rdf:rest N45fa8971893c4023ab2a6f0ce25c133c
137 N1bc39d8de0d2499b8936f92d9448dd19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Middle Aged
139 rdf:type schema:DefinedTerm
140 N30c0a1750a0e4fc99ab4ea6c02230769 rdf:first sg:person.01360660140.37
141 rdf:rest N0b39b6bda4724bba9e386a1857da9bb7
142 N3dd981293645441fa56af3f491236de6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Carcinoma, Squamous Cell
144 rdf:type schema:DefinedTerm
145 N45fa8971893c4023ab2a6f0ce25c133c rdf:first sg:person.01101151164.96
146 rdf:rest Nd5363a2158a245e88fa85c38c5e69d16
147 N4aed640623744b7ea46c981faf91beae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Aged
149 rdf:type schema:DefinedTerm
150 N6ddbe258ac584c75b8e36db1445ad45b schema:name pubmed_id
151 schema:value 20485287
152 rdf:type schema:PropertyValue
153 N76901dcd8f084dbb873108c5182dac5d schema:volumeNumber 102
154 rdf:type schema:PublicationVolume
155 N79c0a6356298491d880ccfc836c034b7 rdf:first sg:person.01331626164.06
156 rdf:rest Nfdf3d7f3d10d48868e7827d972fc203c
157 N7e0a0537b0f04cee90c1e81922637ec3 schema:issueNumber 12
158 rdf:type schema:PublicationIssue
159 N85e2295e725e44cb955c7951536f2d6d schema:name doi
160 schema:value 10.1038/sj.bjc.6605697
161 rdf:type schema:PropertyValue
162 N8b20078b14634b678b530736138ef6ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Male
164 rdf:type schema:DefinedTerm
165 N9ea93177178f4046baea281105ae7703 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Deoxycytidine
167 rdf:type schema:DefinedTerm
168 Nac4d76acc4dc409aaea8c41136c96207 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Palliative Care
170 rdf:type schema:DefinedTerm
171 Naec9de5c26284c7ca3e189d8025d8095 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Disease Progression
173 rdf:type schema:DefinedTerm
174 Nafb51ba3d3d1492680d17dd9b2d3750c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Neoplasm Metastasis
176 rdf:type schema:DefinedTerm
177 Nb392a6e194744b219cb8ea8e0505c939 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Capecitabine
179 rdf:type schema:DefinedTerm
180 Nb467d9069f674113b0bb513855b4d920 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Fluorouracil
182 rdf:type schema:DefinedTerm
183 Nc53ab1faf5eb4db291c6ec0ff85db36e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Neoplasm Recurrence, Local
185 rdf:type schema:DefinedTerm
186 Ncdb6bd486a56480eaf333000ecc8517c rdf:first sg:person.01103254434.93
187 rdf:rest Nd21edc0888c64186acad976823763967
188 Nce0c24b26aed4d03b96f2f10c7d17cca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Platinum Compounds
190 rdf:type schema:DefinedTerm
191 Nd21edc0888c64186acad976823763967 rdf:first sg:person.01322547713.69
192 rdf:rest N30c0a1750a0e4fc99ab4ea6c02230769
193 Nd5363a2158a245e88fa85c38c5e69d16 rdf:first sg:person.01320645107.92
194 rdf:rest N79c0a6356298491d880ccfc836c034b7
195 Nddd0d97124554163b5929b01b9cbbda3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Head and Neck Neoplasms
197 rdf:type schema:DefinedTerm
198 Nfa7d12271bed4e228515ee87fc87571e rdf:first sg:person.01156301535.52
199 rdf:rest Ncdb6bd486a56480eaf333000ecc8517c
200 Nfaf5750f52f04dfa8920052ea2dfc8dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Humans
202 rdf:type schema:DefinedTerm
203 Nfdf3d7f3d10d48868e7827d972fc203c rdf:first sg:person.010151201132.46
204 rdf:rest rdf:nil
205 Nfe2a8b89cd16411b962b6abd7258acfe schema:name Springer Nature - SN SciGraph project
206 rdf:type schema:Organization
207 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
208 schema:name Medical and Health Sciences
209 rdf:type schema:DefinedTerm
210 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
211 schema:name Oncology and Carcinogenesis
212 rdf:type schema:DefinedTerm
213 sg:journal.1017082 schema:issn 0007-0920
214 1532-1827
215 schema:name British Journal of Cancer
216 schema:publisher Springer Nature
217 rdf:type schema:Periodical
218 sg:person.010151201132.46 schema:affiliation grid-institutes:grid.411258.b
219 schema:familyName Cruz
220 schema:givenName J J
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010151201132.46
222 rdf:type schema:Person
223 sg:person.01101151164.96 schema:affiliation grid-institutes:grid.411106.3
224 schema:familyName Gil-Arnaiz
225 schema:givenName I
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101151164.96
227 rdf:type schema:Person
228 sg:person.01103254434.93 schema:affiliation grid-institutes:grid.411050.1
229 schema:familyName Isla
230 schema:givenName D
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103254434.93
232 rdf:type schema:Person
233 sg:person.01132423736.65 schema:affiliation grid-institutes:grid.144756.5
234 schema:familyName Hitt
235 schema:givenName R
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132423736.65
237 rdf:type schema:Person
238 sg:person.01156301535.52 schema:affiliation grid-institutes:grid.411106.3
239 schema:familyName Martinez-Trufero
240 schema:givenName J
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156301535.52
242 rdf:type schema:Person
243 sg:person.01320645107.92 schema:affiliation grid-institutes:grid.411050.1
244 schema:familyName Lambea
245 schema:givenName J
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320645107.92
247 rdf:type schema:Person
248 sg:person.01322547713.69 schema:affiliation grid-institutes:grid.411258.b
249 schema:familyName Adansa
250 schema:givenName J C
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322547713.69
252 rdf:type schema:Person
253 sg:person.01331626164.06 schema:affiliation grid-institutes:grid.411106.3
254 schema:familyName Lecumberri
255 schema:givenName M J
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331626164.06
257 rdf:type schema:Person
258 sg:person.01360660140.37 schema:affiliation grid-institutes:grid.411380.f
259 schema:familyName Irigoyen
260 schema:givenName A
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01360660140.37
262 rdf:type schema:Person
263 sg:pub.10.1038/sj.bjc.6602275 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033665397
264 https://doi.org/10.1038/sj.bjc.6602275
265 rdf:type schema:CreativeWork
266 sg:pub.10.1038/sj.bjc.6602849 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029288237
267 https://doi.org/10.1038/sj.bjc.6602849
268 rdf:type schema:CreativeWork
269 grid-institutes:grid.144756.5 schema:alternateName Medical Oncology Department of University Hospital 12 de Octubre Hospital, Avda. de Córdoba s/n, 28041 Madrid, Spain
270 schema:name Medical Oncology Department of University Hospital 12 de Octubre Hospital, Avda. de Córdoba s/n, 28041 Madrid, Spain
271 rdf:type schema:Organization
272 grid-institutes:grid.411050.1 schema:alternateName Medical Oncology Department of University Hospital Lozano Blesa Hospital, Avda. San Juan Bosco, 15, 50009 Zaragoza, Spain
273 schema:name Medical Oncology Department of University Hospital Lozano Blesa Hospital, Avda. San Juan Bosco, 15, 50009 Zaragoza, Spain
274 rdf:type schema:Organization
275 grid-institutes:grid.411106.3 schema:alternateName Medical Oncology Department of University Hospital Miguel Servet Hospital, Paseo de Isabel La Católica 1-3, 50009 Zaragoza, Spain
276 schema:name Medical Oncology Department of University Hospital Miguel Servet Hospital, Paseo de Isabel La Católica 1-3, 50009 Zaragoza, Spain
277 rdf:type schema:Organization
278 grid-institutes:grid.411258.b schema:alternateName Medical Oncology Department of University Hospital Clínico de Salamanca Hospital, Paseo de San Vicente 58-182, 37007 Salamanca, Spain
279 schema:name Medical Oncology Department of University Hospital Clínico de Salamanca Hospital, Paseo de San Vicente 58-182, 37007 Salamanca, Spain
280 rdf:type schema:Organization
281 grid-institutes:grid.411380.f schema:alternateName Medical Oncology Department of University Hospital Virgen de las Nieves Hospital, Avda de las Fuerzas Armadas, 18014 Granada, Spain
282 schema:name Medical Oncology Department of University Hospital Virgen de las Nieves Hospital, Avda de las Fuerzas Armadas, 18014 Granada, Spain
283 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...